

## Subject: Pfizer extends Lyrica® patent, price increase on 41 drugs

As of December 13, 2018, [The Food and Drug Administration](#) (FDA) awarded [Pfizer](#) a 6-month patent extension for Lyrica, a medication used to treat nerve and muscle pain, including fibromyalgia. It may also be used to treat seizures. This extends the patent through June 30, 2019. In addition, as of January 15, 2019, Pfizer will also increase the list price of 41 medications by 5%.

### Details

The patent extension was based upon results from phase III clinical trials in patients with pediatric epilepsy. This extension allows Pfizer to maintain revenue that would have been lost to generic formulations if the Lyrica patent expired.<sup>1</sup>

There are exceptions to the 5% increase of the 41 medications. Three of those medications will have a 3% increase, while Lyrica itself will have a 9% increase. These exceptions came as a result of recent FDA approvals for additional uses for those medications after extensive development programs.<sup>2</sup>

### The Impact

At this time, First Script shows no impact of this extension and/or price increase.

For more information, please contact your Account Manager or Account Pharmacist.

<sup>1</sup>[https://www.workerscompensation.com/news\\_read.php?id=31075](https://www.workerscompensation.com/news_read.php?id=31075)

<sup>2</sup><https://www.pfizer.com/sites/default/files/news/Pfizer%20Provides%20Transparency%20On%20Drug%20Prices.pdf>